First Time Loading...

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 4.41 HKD 1.38% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

Alphamab Oncology's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Alphamab Oncology is an investment holding company. [ Read More ]

The intrinsic value of one Alphamab Oncology stock under the Base Case scenario is 7.13 HKD. Compared to the current market price of 4.41 HKD, Alphamab Oncology is Undervalued by 38%.

Key Points:
Intrinsic Value
Base Case
7.13 HKD
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Alphamab Oncology

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Alphamab Oncology stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Alphamab Oncology

Provide an overview of the primary business activities
of Alphamab Oncology.

What unique competitive advantages
does Alphamab Oncology hold over its rivals?

What risks and challenges
does Alphamab Oncology face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Alphamab Oncology.

Provide P/S
for Alphamab Oncology.

Provide P/E
for Alphamab Oncology.

Provide P/OCF
for Alphamab Oncology.

Provide P/FCFE
for Alphamab Oncology.

Provide P/B
for Alphamab Oncology.

Provide EV/S
for Alphamab Oncology.

Provide EV/GP
for Alphamab Oncology.

Provide EV/EBITDA
for Alphamab Oncology.

Provide EV/EBIT
for Alphamab Oncology.

Provide EV/OCF
for Alphamab Oncology.

Provide EV/FCFF
for Alphamab Oncology.

Provide EV/IC
for Alphamab Oncology.

Show me price targets
for Alphamab Oncology made by professional analysts.

What are the Revenue projections
for Alphamab Oncology?

How accurate were the past Revenue estimates
for Alphamab Oncology?

What are the Net Income projections
for Alphamab Oncology?

How accurate were the past Net Income estimates
for Alphamab Oncology?

What are the EPS projections
for Alphamab Oncology?

How accurate were the past EPS estimates
for Alphamab Oncology?

What are the EBIT projections
for Alphamab Oncology?

How accurate were the past EBIT estimates
for Alphamab Oncology?

Compare the revenue forecasts
for Alphamab Oncology with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Alphamab Oncology and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Alphamab Oncology against its competitors.

Analyze the profit margins
(gross, operating, and net) of Alphamab Oncology compared to its peers.

Compare the P/E ratios
of Alphamab Oncology against its peers.

Discuss the investment returns and shareholder value creation
comparing Alphamab Oncology with its peers.

Analyze the financial leverage
of Alphamab Oncology compared to its main competitors.

Show all profitability ratios
for Alphamab Oncology.

Provide ROE
for Alphamab Oncology.

Provide ROA
for Alphamab Oncology.

Provide ROIC
for Alphamab Oncology.

Provide ROCE
for Alphamab Oncology.

Provide Gross Margin
for Alphamab Oncology.

Provide Operating Margin
for Alphamab Oncology.

Provide Net Margin
for Alphamab Oncology.

Provide FCF Margin
for Alphamab Oncology.

Show all solvency ratios
for Alphamab Oncology.

Provide D/E Ratio
for Alphamab Oncology.

Provide D/A Ratio
for Alphamab Oncology.

Provide Interest Coverage Ratio
for Alphamab Oncology.

Provide Altman Z-Score Ratio
for Alphamab Oncology.

Provide Quick Ratio
for Alphamab Oncology.

Provide Current Ratio
for Alphamab Oncology.

Provide Cash Ratio
for Alphamab Oncology.

What is the historical Revenue growth
over the last 5 years for Alphamab Oncology?

What is the historical Net Income growth
over the last 5 years for Alphamab Oncology?

What is the current Free Cash Flow
of Alphamab Oncology?

Discuss the annual earnings per share (EPS)
trend over the past five years for Alphamab Oncology.

Financials

Balance Sheet Decomposition
Alphamab Oncology

Current Assets 1.7B
Cash & Short-Term Investments 1.6B
Receivables 78.2m
Other Current Assets 62.9m
Non-Current Assets 605.7m
PP&E 604.7m
Other Non-Current Assets 937k
Current Liabilities 261.3m
Accounts Payable 19.4m
Accrued Liabilities 123.7m
Other Current Liabilities 118.1m
Non-Current Liabilities 220.3m
Long-Term Debt 202.3m
Other Non-Current Liabilities 17.9m
Efficiency

Earnings Waterfall
Alphamab Oncology

Revenue
218.8m CNY
Cost of Revenue
-55.2m CNY
Gross Profit
163.5m CNY
Operating Expenses
-362m CNY
Operating Income
-198.4m CNY
Other Expenses
-12.2m CNY
Net Income
-210.6m CNY

Free Cash Flow Analysis
Alphamab Oncology

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

Profitability Score
Profitability Due Diligence

Alphamab Oncology's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Exceptional 1-Year Revenue Growth
31/100
Profitability
Score

Alphamab Oncology's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Alphamab Oncology's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Alphamab Oncology's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Alphamab Oncology

Wall Street analysts forecast Alphamab Oncology stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 10.12 HKD with a low forecast of 5.35 HKD and a high forecast of 21 HKD.

Lowest
Price Target
5.35 HKD
21% Upside
Average
Price Target
10.12 HKD
130% Upside
Highest
Price Target
21 HKD
376% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Alphamab Oncology

1M 1M
-2%
6M 6M
-58%
1Y 1Y
-73%
3Y 3Y
-66%
5Y 5Y
-67%
10Y 10Y
-67%
Annual Price Range
4.41
52w Low
3.86
52w High
16.04
Price Metrics
Average Annual Return -3.44%
Standard Deviation of Annual Returns 17.48%
Max Drawdown -86%
Shares Statistics
Market Capitalization 4.3B HKD
Shares Outstanding 964 844 032
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Alphamab Oncology Logo
Alphamab Oncology

Country

China

Industry

Biotechnology

Market Cap

4.3B HKD

Dividend Yield

0%

Description

Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.

Contact

JIANGSU
Suzhou
No. 175, Fangzhou Road, Suzhou Industrial Park
http://www.alphamabonc.com/en/

IPO

2019-12-12

Employees

366

Officers

Founder, Executive Chairman & CEO
Dr. Ting Xu Ph.D.
VP of Corporate Operations & Executive Director
Ms. Yang Liu
Director of Investor Relations & Joint Company Secretary
Ms. Jin'nan Wang
Vice President of Government Affairs & Public Relations
Mr. Yumin Wan
Senior Vice President of Business Development
Dr. Mike Liu M.B.A., Ph.D.
Chief Commercial Officer
Mr. Jing Han
Show More
Joint Company Secretary
Ms. Lok Yee Chan A.C.I.S., A.C.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one Alphamab Oncology stock?

The intrinsic value of one Alphamab Oncology stock under the Base Case scenario is 7.13 HKD.

Is Alphamab Oncology stock undervalued or overvalued?

Compared to the current market price of 4.41 HKD, Alphamab Oncology is Undervalued by 38%.